Hazlett Burt & Watson Inc. Has $277,000 Stock Holdings in Bristol Myers Squibb Company $BMY

Hazlett Burt & Watson Inc. decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,003 shares of the biopharmaceutical company’s stock after selling 425 shares during the period. Hazlett Burt & Watson Inc.’s holdings in Bristol Myers Squibb were worth $277,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC lifted its stake in Bristol Myers Squibb by 193.6% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 535,902 shares of the biopharmaceutical company’s stock valued at $25,461,000 after purchasing an additional 353,392 shares during the last quarter. RHS Financial LLC bought a new position in Bristol Myers Squibb in the 2nd quarter valued at approximately $459,000. OFI Invest Asset Management lifted its stake in Bristol Myers Squibb by 33.7% in the 2nd quarter. OFI Invest Asset Management now owns 1,689 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 426 shares during the last quarter. Sippican Capital Advisors lifted its stake in Bristol Myers Squibb by 1.4% in the 2nd quarter. Sippican Capital Advisors now owns 56,392 shares of the biopharmaceutical company’s stock valued at $2,610,000 after purchasing an additional 770 shares during the last quarter. Finally, Advocate Group LLC lifted its stake in Bristol Myers Squibb by 4.8% in the 2nd quarter. Advocate Group LLC now owns 154,239 shares of the biopharmaceutical company’s stock valued at $7,140,000 after purchasing an additional 7,088 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on BMY shares. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Saturday, September 27th. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Finally, Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fifteen have issued a Hold rating to the company. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $57.14.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.07% of the company’s stock.

Bristol Myers Squibb Trading Down 0.9%

NYSE:BMY opened at $43.55 on Tuesday. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The stock has a market capitalization of $88.63 billion, a price-to-earnings ratio of 17.56, a PEG ratio of 2.26 and a beta of 0.33. The firm has a fifty day simple moving average of $46.22 and a two-hundred day simple moving average of $47.84. Bristol Myers Squibb Company has a 12 month low of $42.96 and a 12 month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business’s quarterly revenue was up .6% on a year-over-year basis. During the same period last year, the company posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.7%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.